Market Dynamics:

The global hyperlipidemia treatment market exhibited significant strength in 2021 and is poised to experience a rapid compound annual growth rate (CAGR) in revenue over the forecast period. This growth is attributed to the expanding target population and heightened awareness of the cardiovascular disease (CVD) risks associated with persistent hyperlipidemia. However, the global hyperlipidemia treatment market faces potential challenges due to adverse effects associated with antihyperlipidemic medications.

Hyperlipidemia encompasses various inherited and acquired disorders characterized by abnormally high levels of lipids in the body. It is a prevalent condition, especially in the Western hemisphere, but it also has a global presence. Hyperlipidemia is typically defined as having Low-Density Lipoprotein (LDL), total cholesterol, triglyceride levels, or lipoprotein levels exceeding 90% of the population or having High-Density Lipoprotein (HDL) levels lower than 10% of the population compared to the general populace.

Get a sample copy of the Hyperlipidemia Treatment Market report: https://www.reportsanddata.com/download-free-sample/5257

Factors Supporting Market Growth:

Drivers: Numerous factors contribute to the growth of the hyperlipidemia market. A survey conducted by the American Heart Association reported a hyperlipidemia prevalence of 11.9%, with over 28.5 million individuals aged 20 and above having high cholesterol levels. The number of adults diagnosed with hyperlipidemia in the U.S. and Europe has exceeded three million and continues to rise. The increasing elderly and geriatric population is expected to be a driving force behind market growth. The World Health Organization predicts that the global geriatric population, which was around 524 million in 2010, will reach approximately 2 billion by 2050. Moreover, the growth of the market is influenced by hyperlipidemia guidelines in the U.S., particularly those addressing statin dosage regimens for individuals aged 21 and older at risk of developing Atherosclerotic Cardiovascular Disease (ASCVD). This results in an expanding group of patients eligible for statin treatment. Additionally, the growing diagnosis of hyperlipidemia, often due to unhealthy dietary habits, contributes to market growth.

Restraints: Patients with hyperlipidemia exhibit a wide range of responses to treatment, with many being intolerant to or unresponsive to statins. These factors indirectly reduce the number of individuals using statins for treatment. Anti-hyperlipidemic drugs are associated with various gastrointestinal adverse effects that hinder market growth. The lack of trained professionals for treatment and limited public awareness about this condition are also barriers to market growth.

Opportunities: The expiration of the patent for drugs like Vascepa by Amarin Corporation paves the way for the generic market. Increasing research and development activities by pharmaceutical companies for targeted hyperlipidemia treatments are expanding the market. Novel treatments, such as human monoclonal antibodies like evolocumab and alirocumab, which block the action of the proprotein convertase subtilisin-kexin type 9 Enzyme (PCSK-9), are under study. PCSK-9 is a protein that binds to hepatic LDL receptors and LDL cholesterol. Raising awareness and education about hyperlipidemia can further drive market growth.

Fastest-growing Region: The Asia Pacific market is projected to register a significant CAGR in revenue over the forecast period. Countries like China and India are witnessing substantial increases in their geriatric populations. The presence of generic drug manufacturers and expanding healthcare facilities will accelerate the region's growth rate.

Competitive Landscape:

Both organic and inorganic strategies are being employed by companies in the market. For example, Akums Drugs & Pharmaceuticals received authorization from DCGI and CDSCO to manufacture and market bempedoic acid, a novel medicine for treating high LDL cholesterol levels. The US Food and Drug Administration (FDA) approved Leqvio (inclisiran), developed by Novartis, as the first and only siRNA therapy for lowering LDL cholesterol levels.

Major Companies in the Market:

• AstraZeneca
• Sun Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Johnson & Johnson Private Limited
• Reckitt Benckiser Group plc.
• Novartis AG
• Reddy’s Laboratories Ltd
• GlaxoSmithKline plc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Daiichi Sankyo Company, Limited
• Amgen Inc.

End-Use Outlook (Revenue, USD Billion; 2019-2030):

• Hospital Pharmacies
• Retailer Pharmacies
• Online Pharmacy Stores

Type Outlook (Revenue, USD Billion; 2019-2030):

• Familial
• Acquired

Route of Administration Outlook (Revenue, USD Billion; 2019-2030):

• Oral
• Parenteral
• Others

Treatment Outlook (Revenue, USD Billion; 2019-2030):

• Statins
• PCSK9 Inhibitors
• Bile Acid Sequestrants
• Cholesterol Absorption Inhibitors
• Fibric Acid Derivatives
• Combination
• Others

Dosage Form Outlook (Revenue, USD Billion; 2019-2030):

• Tablets
• Injections
• Others

Regional Outlook (Revenue, USD Billion; 2019-2030):

• North America (U.S., Canada, Mexico)
• Europe (Germany, UK, France, Italy, Spain, Benelux, Rest of Europe)
• Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
• Latin America (Brazil, Rest of Latin America)
• Middle East & Africa (Saudi Arabia, UAE, South Africa)

Explore Trending Reports:

Smart Governments Market-https://www.globenewswire.com/news-release/2019/12/17/1961293/0/en/Smart-Governments-Market-To-Reach-USD-52-19-Billion-By-2026-Reports-And-Data.html

Procure To Pay Software Market-https://www.globenewswire.com/news-release/2019/09/05/1911800/0/en/Procure-To-Pay-Software-Market-To-Reach-USD-9-2-Billion-By-2026-Reports-And-Data.html

Advanced Metering Infrastructure Market-https://www.globenewswire.com/news-release/2020/03/05/1996060/0/en/Advanced-Metering-Infrastructure-Market-To-Reach-USD-21-05-Billion-By-2026-Reports-And-Data.html

Request a customization of the report: https://www.reportsanddata.com/request-customization-form/5257

Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.

About Reports and Data    

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports

Browse More Latest Reports @ https://www.reportsanddata.com/report

Browse Latest Blogs: https://www.reportsanddata.com/blogs

Browse Latest Press Release: https://www.reportsanddata.com/press-release